| 2023, Cilt 21, Sayı 1, Sayfa(lar) 007-012 |
|
|
Serum Glypican-3 and Interleukin-6 Levels in COVID-19 Patients |
Ayşe Basmakcı1, Esra Gürdl2, Ayşe Selcen Pala3, Orkide Kutlu3, Mine Adaş3, Mustafa Şahi4, Fatih İncirku6, Çiğdem Arabacı5, Okan Dikker6 |
1Beykoz Devlet Hastanesi, İç Hastalıkları, İstanbul, Türkiye
2Sağlık Bilimleri Üniversitesi Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Radyoloji, İstanbul, Türkiye
3Sağlık Bilimleri Üniversitesi İstanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, İç Hastalıkları, İstanbul, Türkiye
4Hitit Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya, Çorum, Türkiye
5Sağlık Bilimleri Üniversitesi İstanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, Tıbbi mikrobiyoloji, İstanbul, Türkiye
6Sağlık Bilimleri Üniversitesi İstanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, Tıbbi Biyokimya, İstanbul, Türkiye |
Keywords: Glypican-3; IL-6; COVID-19 |
Aim: We aimed to determine the glypican-3 levels in patients diagnosed with COVID-19, compare these values with the healthy controls, and analyze the evaluation of glypican-3 levels with inflammatory markers, including interleukin-6 (IL-6), to determine its role in disease pathogenesis.
Material and Methods: A total of 88 participants (58 patients and 30 controls) were included. Medical history and laboratory findings of the population were recorded. Serum glypican-3 and IL-6 levels were analyzed by the Enzyme-linked immunosorbent assay method.
Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH) levels, and IL-6 levels were significantly higher in the COVID-19 patient group than the healthy controls, while glypican-3 levels were significantly lower in the patient group (p<0.001). Glypican-3 levels significantly and inversely correlated with serum AST, CRP, ferritin, IL-6, and LDH levels (p<0.05).
Conclusions: We found that the levels of glypican-3 decreased in COVID-19 patients. Additionally, serum glypican-3 levels are inversely correlated with CRP and IL-6 levels. Targeting glypican-3 may be useful in understanding the pathophysiology of COVID-19.
|
|
|
|
